Rhonda L. Bitting
About
Rhonda L. Bitting is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Rhonda L. Bitting has authored 62 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Rhonda L. Bitting's work include Prostate Cancer Treatment and Research (36 papers), Prostate Cancer Diagnosis and Treatment (15 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Rhonda L. Bitting is often cited by papers focused on Prostate Cancer Treatment and Research (36 papers), Prostate Cancer Diagnosis and Treatment (15 papers) and Radiopharmaceutical Chemistry and Applications (9 papers). Rhonda L. Bitting collaborates with scholars based in United States, Canada and United Kingdom. Rhonda L. Bitting's co-authors include Andrew J. Armstrong, Daniel J. George, Gabor Kemeny, Mariano A. García-Blanco, James Turnbull, Matthew S. Marengo, Christina I. Herold, P. Kelly Marcom, Sebastian Oltean and Krista Noonan and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and PLoS ONE.
In The Last Decade
Rhonda L. Bitting
60 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rhonda L. Bitting United States | 18 | 930 | 878 | 747 | 731 | 221 | 62 | 2.0k | ||
| Holly M. Nguyen United States | 21 | 1.3k 1.4× | 598 0.7× | 934 1.3× | 612 0.8× | 241 1.1× | 55 | 2.1k | ||
| Daniel Nava Rodrigues United Kingdom | 26 | 1.0k 1.1× | 878 1.0× | 948 1.3× | 820 1.1× | 177 0.8× | 54 | 2.2k | ||
| Dana T. Aftab United States | 20 | 574 0.6× | 882 1.0× | 803 1.1× | 417 0.6× | 112 0.5× | 45 | 1.8k | ||
| Daniel Escuín Spain | 17 | 489 0.5× | 671 0.8× | 1.2k 1.6× | 980 1.3× | 193 0.9× | 26 | 2.1k | ||
| Bianca Maria Veneziani Italy | 22 | 689 0.7× | 821 0.9× | 1.0k 1.4× | 338 0.5× | 114 0.5× | 51 | 2.0k | ||
| Stephen Leong United States | 23 | 471 0.5× | 1.1k 1.3× | 842 1.1× | 606 0.8× | 87 0.4× | 73 | 2.3k | ||
| Sanna-Maria Käkönen Finland | 19 | 644 0.7× | 2.1k 2.3× | 1.8k 2.5× | 797 1.1× | 521 2.4× | 41 | 3.7k | ||
| Dorthe Grabau Sweden | 28 | 510 0.5× | 1.5k 1.7× | 1.3k 1.8× | 1.6k 2.2× | 222 1.0× | 57 | 3.0k | ||
| Vincenzo Damiano Italy | 26 | 1.2k 1.2× | 1.9k 2.1× | 1.4k 1.8× | 459 0.6× | 336 1.5× | 62 | 3.2k | ||
| Tina Cascone United States | 30 | 1.6k 1.7× | 1.8k 2.1× | 1.4k 1.8× | 684 0.9× | 194 0.9× | 104 | 3.4k |
Countries citing papers authored by Rhonda L. Bitting
Since
Specialization
Citations
This map shows the geographic impact of Rhonda L. Bitting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhonda L. Bitting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhonda L. Bitting more than expected).
Fields of papers citing papers by Rhonda L. Bitting
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rhonda L. Bitting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhonda L. Bitting. The network helps show where Rhonda L. Bitting may publish in the future.
Co-authorship network of co-authors of Rhonda L. Bitting
This figure shows the co-authorship network connecting the top 25 collaborators of Rhonda L. Bitting. A scholar is included among the top collaborators of Rhonda L. Bitting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhonda L. Bitting. Rhonda L. Bitting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yu, Evan Y., R. Bryan Rumble, Neeraj Agarwal, et al.. (2025). Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology. 43(6). 748–758.
2.
Tabriz, Amir Alishahi, Matthew J. Boyer, Adelaide M. Gordon, et al.. (2025). Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer. Annals of Internal Medicine. 178(2). 218–228.
3.
Barata, Pedro C., Karlynn E. Neu, Jennifer La, et al.. (2025). Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 154–154.
4.
Bitting, Rhonda L., Janet A. Tooze, Michael Goodman, et al.. (2024). Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma. Cancer Research Communications. 4(2). 530–539.
5.
Howard, Lauren E., Bridget F. Koontz, Scott T. Tagawa, et al.. (2024). Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. European Urology Oncology. 8(2). 287–295.
6.
George, Daniel J., Neeraj Agarwal, Krishnan Ramaswamy, et al.. (2024). Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. 27(4). 765–775.
7.
Zhang, Tian, Lauren E. Howard, Bridget F. Koontz, et al.. (2023). Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. Journal of Clinical Oncology. 41(16_suppl). 5016–5016.
8.
Bitting, Rhonda L., Yuan Wu, Jason A. Somarelli, et al.. (2023). Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial. JCO Precision Oncology. 7(7). e2300214–e2300214.
9.
Hanson, Erik D., Alexander R. Lucas, Young E. Whang, et al.. (2022). Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 26(2). 302–308.
10.
Freedland, Stephen J., Rickard Sandin, Scott T. Tagawa, et al.. (2021). 609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. Annals of Oncology. 32. S650–S651.
11.
Bitting, Rhonda L., Patrick Healy, Daniel J. George, et al.. (2020). Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology. 4(6). 948–954.
12.
Labriola, Matthew, et al.. (2020). Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer and Prostatic Diseases. 24(2). 301–309.
13.
Praharaj, Prakash Priyadarshi, Sujit K. Bhutia, Sunitha Nagrath, Rhonda L. Bitting, & Gagan Deep. (2018). Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1869(2). 117–127.
14.
Peak, Taylor, Nicole P. Kasica, Gatikrushna Panigrahi, et al.. (2017). Abstract 3187: Role of exosome secretion in the survival of enzalutamide-resistant prostate cancer cells: Syntaxin 6 as a novel therapeutic target. Cancer Research. 77(13_Supplement). 3187–3187.
15.
Armstrong, Andrew J., Susan Halabi, Patrick Healy, et al.. (2017). Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. European Journal of Cancer. 81. 228–236.
16.
Gupta, Santosh, Jing Li, Gabor Kemeny, et al.. (2016). Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 23(5). 1346–1357.
17.
Bitting, Rhonda L., Patrick Healy, Patricia Creel, et al.. (2013). A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 12(4). 241–250.
18.
Bitting, Rhonda L. & Andrew J. Armstrong. (2013). Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. The Cancer Journal. 19(1). 25–33.
19.
Bitting, Rhonda L. & Andrew J. Armstrong. (2013). Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine Related Cancer. 20(3). R83–R99.
20.
Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, et al.. (2011). Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers. Molecular Cancer Research. 9(8). 997–1007.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Holly M. Nguyen Breakdown of academic impact, for papers by Daniel Nava Rodrigues Breakdown of academic impact, for papers by Dana T. Aftab Breakdown of academic impact, for papers by Daniel Escuín Breakdown of academic impact, for papers by Bianca Maria Veneziani Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Sanna-Maria Käkönen Breakdown of academic impact, for papers by Dorthe Grabau Breakdown of academic impact, for papers by Vincenzo Damiano Breakdown of academic impact, for papers by Tina Cascone